Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia

Critical Care Medicine

Volumn 37, Issue 7, 2009, Pages 2181-2186

  Nagato, Masaru ^a   Okamoto, Kohji ^a   Abe, Yukio ^a   Higure, Aiichiro ^a   Yamaguchi, Koji ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Cytokine; Endotoxemia; High mobility group box 1 protein; Lipopolysaccharide; Recombinant human soluble thrombomodulin; Thrombomodulin

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTITHROMBIN III; ASPARTATE AMINOTRANSFERASE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; RECOMBINANT THROMBOMODULIN; THROMBIN ANTITHROMBIN COMPLEX; TUMOR NECROSIS FACTOR ALPHA; ANTITHROMBIN III PROTEASE COMPLEX; ANTITHROMBIN III-PROTEASE COMPLEX; HBP1 PROTEIN, RAT; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE, E. COLI 026 B6; LIPOPOLYSACCHARIDE, E. COLI 026-B6; PEPTIDE HYDROLASE; RECOMBINANT PROTEIN; THROMBOMODULIN;

ACUTE LIVER INJURY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENDOTOXEMIA; HISTOPATHOLOGY; LIVER DYSFUNCTION; LIVER INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SURVIVAL RATE; TREATMENT OUTCOME; ANIMAL; BLOOD; DISEASE MODEL; LIVER; LIVER DISEASE; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTITHROMBIN III; DISEASE MODELS, ANIMAL; ENDOTOXEMIA; HMGB1 PROTEIN; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; LIVER; LIVER DISEASES; MALE; PEPTIDE HYDROLASES; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; THROMBOMODULIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67649766887     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181a55184     Document Type: Article

References (43)

1. Wang H, Yang H, Czura CJ, et al: HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 2001; 164: 1768-1773
2. Wang H, Bloom O, Zhang M, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285:248-251
3. Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-195
4. Schmidt AM, Yan SD, Yan SF, et al: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108:949-955
5. Wang H, Vishnubhakat JM, Bloom O, et al: Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999; 126:389-392
6. Yang H, Ochani M, Li J, et al: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004; 101:296-301
7. Fiuza C, Bustin M, Talwar S, et al: Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101:2652-2660
8. Sunden-Cullberg J, Norby-teglund A, Treutiger CJ: The role of high mobility group box-1 protein in severe sepsis. Curr Opin Infect Dis 2006; 19:231-236
9. Esmon CT: The interactions between inflammation and coagulation. Br J Haematol 2005; 131:417-430
10. Esmon CT: The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-1352
11. Grey ST, Tsuchida A, Hau H, et al: Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol 1994; 153:3664-3672
12. Abeyama K. Stern DM, Ito Y, et al: The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115:1267-1274
13. Mohri M, Oka M, Aoki Y, et al: Intravenous extended infusion of recombinant human soluble thrombomodulin prevented tissue factor-induced disseminated intravascular coagulation in rats. Am J Hematol 1994; 45: 298-303
14. Dijkstra CD, Döpp EA, Joling P, et al: The heterogeneity of mononuclear phagocytes in lymphoid organs: Distinct macrophage sub-populations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology 1985; 54:589-599
15. Abraham E, Arcaroli J, Carmody A, et al: HMG-1 as a mediator of acute lung inflammation. J Immunol 2000; 15:2950-2954
16. Degryse B, Bonaldi T, Scaffidi P, et al: The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001; 152: 1197-1206
17. Müller S, Scaffidi P, Degryse B, et al: The double life of HMGB1 chromatin protein: Architectural factor and extracellular signal. EMBO J 2001; 20:4337-4340
18. Falciola L, Spada F, Calogero S, et al: High mobility group 1 protein is not stably associated with the chromosomes of somatic cells. J Cell Biol 1997; 137:19-26
19. Waage A, Halstensen A, Espevik T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 1:355-357
20. Okusawa S, Gelfand JA, Ikejima T, et al: Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81:1162-1172
21. Toshima K, Mochida S, Ishikawa K, et al: Contribution of CD14 to endotoxin-induced liver injury may depend on types of macrophage activation in rats. Biochem Biophys Res Commun 1998; 246:731-735
22. Yamanobe F, Mochida S, Ohno A, et al: Recombinant human tissue factor pathway inhibitor as a possible anticoagulant targeting hepatic sinusoidal walls. Thromb Res 1997; 85:493-501
23. Alexander HR, Doherty GM, Venzon DJ, et al: Recombinant interleukin-1 receptor antagonist (IL-1ra): Effective therapy against gramnegative sepsis in rats. Surgery 1992; 112: 188-193
24. Opal SM, Cross AS, Sadoff JC, et al: Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis. J Clin Invest 1991; 88:885-890
25. Hagiwara S, Iwasaka H, Matsumoto S, et al: High dose antithrombin III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats. Intensive Care Med 2008; 34: 361-367
26. Akahane K, Okamoto K, Kikuchi M, et al: Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide-induced endotoxemia in rats. Surgery 2001; 130:809-818
27. Riedemann NC, Guo RF, Ward PA: Novel strategies for the treatment of sepsis. Nat Med 2003; 9:517-524
28. McCloskey RV, Strabe RC, Sanders C, et al: Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 1994; 121:1-5
29. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273:934-941
30. Fisher CJ Jr, Dhainaunt JF, Opal SM, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271:1836-1843
31. Riedemann NC, Guo RF, Ward PA, et al: The enigma of sepsis. J Clin Invest 2003; 112: 460-467
32. Warren BL, Eid A, Singer P, et al: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286: 1869-1878
33. Riewald M, Petrovan RJ, Donner A, et al: Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296:1880-1882
34. Esmon CT, Owen WG: Identification of an endothelial cell cofactor for thrombincatalyzed activation of protein C. Proc Natl Acad Sci USA 1981; 78:2249-2252
35. Esmon CT, Esmon NL, Harris KW: Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 1982; 257:7944-7947
36. Maruyama I, Salem HM, Majerus PW: Coagulation factor Va binds to human umbilical vein endothelial cells and accelerates protein C activation. J Clin Invest 1984; 74: 224-230
37. Esmon CT: The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-4746
38. Suzuki K, Kusumoto H, Deyashiki Y, et al: Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987; 6:1891-1897
39. Zushi M, Gomi K, Yamamoto S, et al: The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity. J Biol Chem 1989; 264:10351-10353
40. Esmon CT: Regulation of blood coagulation. Biochim Biophys Acta 2000; 1477: 349-360
41. Mohri M, Sugimoto E, Sata M, et al: The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation - A comparison with other anticoagulants. Thromb Haemost 1999; 82:687-693
42. Ito T, Kawahara K, Nakamura T, et al: High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost 2006; 5:109-116
43. Saito H, Maruyama I, Shimazaki S, et al: Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: Results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5:31-41